FAME 1 Eye research study - A new treatment for retinopathy in type 1 diabetes

Type 1 diabetes with eye changes (retinopathy)

Fenofibrate has proved to slow the development of diabetic retinopathy and need for laser surgery for people with type 2 diabetes. The purpose of this study is to test whether Fenofibrate is also safe and effective in reducing retinopathy for people with type 1 diabetes.

Trial Status
Trial Phase
Phase 3 Drug Trial
Trial contact details
Contact Person
Yvonne Gautam
What you need to know

Who can take part?

  • People with type 1 diabetes.
  • Those aged 18 years or over
  • People with at least one eye with mild non-proliferative diabetic eye disease (retinopathy)

What is involved for you?

  • vital signs taken (blood pressure, heart rate), height, weight
  • electro cardiograms (ECGs)
  • simple tests of foot sensation
  • eye tests and photos taken
  • blood and urine samples
  • questionnaires

Trial dates

This trial is accepting participants until June 2024.

All research clinical trials news

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Working as a research assistant in an immunology research lab, Yvonne Gautam learnt what a clinical trial was after being asked to set up a lab for a Phase Two clinical trial.



Clinical Trials Coordinator Yvonne Gautam is working towards creating better treatments for patients with diabetes

Displaying results 1-3 (of 16)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|